Can a common diabetes drug help pancreatic cancer patients control blood sugar?
NCT ID NCT06168812
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This phase 2 trial is testing the safety and effectiveness of glipizide, a standard diabetes drug, for lowering blood sugar in people with pancreatic cancer. The study includes 29 participants with active pancreatic cancer and high blood sugar. Researchers will measure blood sugar levels before and after starting glipizide to see if it helps control hyperglycemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glipizide (a sulfonylurea drug that helps lower blood sugar)
What this could lead to
If successful, this could provide a safe and effective way to manage high blood sugar in people with pancreatic cancer, improving their overall care.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. Glipizide can cause low blood sugar, and its long-term effects in this specific group are not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.